- Home
- MKTW vs ATNM Comparison
MKTW vs ATNM Comparison
Compare MKTW & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKTW
- ATNM
- Stock Information
- Founded
- MKTW 1999
- ATNM 2000
- Country
- MKTW United States
- ATNM United States
- Employees
- MKTW N/A
- ATNM N/A
- Industry
- MKTW Computer Software: Prepackaged Software
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- MKTW Technology
- ATNM Health Care
- Exchange
- MKTW Nasdaq
- ATNM Nasdaq
- Market Cap
- MKTW 48.2M
- ATNM 51.5M
- IPO Year
- MKTW N/A
- ATNM N/A
- Fundamental
- Price
- MKTW $17.30
- ATNM $1.71
- Analyst Decision
- MKTW
- ATNM Strong Buy
- Analyst Count
- MKTW 0
- ATNM 3
- Target Price
- MKTW N/A
- ATNM $4.67
- AVG Volume (30 Days)
- MKTW 27.9K
- ATNM 212.6K
- Earning Date
- MKTW 05-08-2025
- ATNM 05-09-2025
- Dividend Yield
- MKTW 4.13%
- ATNM N/A
- EPS Growth
- MKTW 207.28
- ATNM N/A
- EPS
- MKTW 3.12
- ATNM N/A
- Revenue
- MKTW $383,217,000.00
- ATNM N/A
- Revenue This Year
- MKTW N/A
- ATNM N/A
- Revenue Next Year
- MKTW $0.42
- ATNM N/A
- P/E Ratio
- MKTW $5.77
- ATNM N/A
- Revenue Growth
- MKTW N/A
- ATNM N/A
- 52 Week Low
- MKTW $9.08
- ATNM $1.03
- 52 Week High
- MKTW $29.00
- ATNM $8.64
- Technical
- Relative Strength Index (RSI)
- MKTW 60.15
- ATNM 59.45
- Support Level
- MKTW $16.19
- ATNM $1.51
- Resistance Level
- MKTW $18.78
- ATNM $1.69
- Average True Range (ATR)
- MKTW 0.96
- ATNM 0.11
- MACD
- MKTW -0.11
- ATNM -0.01
- Stochastic Oscillator
- MKTW 55.95
- ATNM 71.26
About MKTW MarketWise Inc.
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms including mobile, desktops, and tablets.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.